Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in shares of its common stock (the “Shares”) and $250,000,000 aggregate principal amount of convertible senior notes due 2024 (the “Notes”). In addition, Repligen expects to grant the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to $15,000,000 of additional Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37,500,000 aggregate principal amount of additional Notes solely to cover over-allotments. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed or as to the actual size or terms of the offerings. Neither offering is contingent on the completion of the other offering. 
The Notes will be
news icon
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
news icon
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
corporate icon
High Productivity Harvest
High Productivity Harvest (HPH) is a novel application developed by Repligen that enables the harvest of a Fed-Batch bioreactor in a fully sterile manner ready for processing on a capture column, eliminating both centrifugation and depth filtration.
corporate icon
SpectraPor® Biotech Grade Regenerated Cellulose (RC) Dialysis Membrane
Molecular porous Biotech Grade Regenerated Cellulose (RC) membrane is produced for more challenging lab-scale dialysis applications that require high molecular selectivity as well as a membrane with higher purity and compatibility to harsh conditions.
corporate icon
SpectraPor® Float-A-Lyzer®
Ready-to-use dialysis devices are all made with proprietary Biotech Grade CE dialysis tubing, pre-assembled with volume specific lengths of membrane tubing and designed to maximize convenience, ease-of-use and sample recovery.
corporate icon
SpectraPor® Tube-A-Lyzer®
Ready-to-use dialysis devices are all made with our proprietary Biotech Grade CE dialysis tubing, preassembled with volume specific lengths of membrane tubing and designed to maximize convenience, ease-of-use and sample recovery.
corporate icon
Metabolomics
Challenge: Understanding cellular metabolism is essential, but metabolite shifts are transient and easily missed in offline workflows. Our Solution: With REBEL XT, real-time monitoring of nutrient consumption and byproduct accumulation drives smarter decisions on feed timing and culture viability.
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $271.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 10, 2020 subject to customary closing conditions.

Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 3, 2019 subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. These securities